---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-000191"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:09:50.452433+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025

## Summary
- IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.
- SP-26 ketamine implant for fibromyalgia nearing first animal studies in early 2025; aims for at-home injectable therapeutic.
- Both SPC-15 and SP-26 may qualify for FDA's streamlined 505(b)(2) approval pathway, reducing costs and time.
- Cash on hand and minimal debt provide financial flexibility; no specific financial guidance disclosed.
- Exclusive global license from Columbia University for SPC-15 pre-clinical development.

## SEC filing metadata
- accession: 0001213900-25-000191
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390025000191/0001213900-25-000191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390025000191/ea0226314-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-000191
- JSON: https://secwatch.observer/filing/0001213900-25-000191.json
- Plain text: https://secwatch.observer/filing/0001213900-25-000191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.